vs
安道拓（ADNT）与徕博科（LH）财务数据对比。点击上方公司名可切换其他公司
安道拓的季度营收约是徕博科的1.0倍（$3.6B vs $3.5B），徕博科净利率更高（4.7% vs -0.6%，领先5.3%），徕博科同比增速更快（5.6% vs 4.3%），徕博科自由现金流更多（$490.3M vs $15.0M），过去两年徕博科的营收复合增速更高（5.2% vs -1.4%）
安道拓是全球规模最大的汽车座椅制造商，注册地位于爱尔兰，运营总部设在美国密歇根州普利茅斯，业务覆盖全球各地，为全球客户提供专业的汽车座椅相关产品及解决方案，在汽车座椅领域拥有领先的市场地位与技术优势。
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
ADNT vs LH — 直观对比
营收规模更大
ADNT
是对方的1.0倍
$3.5B
营收增速更快
LH
高出1.3%
4.3%
净利率更高
LH
高出5.3%
-0.6%
自由现金流更多
LH
多$475.3M
$15.0M
两年增速更快
LH
近两年复合增速
-1.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $3.5B |
| 净利润 | $-22.0M | $164.7M |
| 毛利率 | 6.0% | 28.2% |
| 营业利润率 | 1.1% | 7.6% |
| 净利率 | -0.6% | 4.7% |
| 营收同比 | 4.3% | 5.6% |
| 净利润同比 | — | 14.9% |
| 每股收益（稀释后） | $-0.28 | $1.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADNTLH
| Q4 25 | $3.6B | $3.5B | ||
| Q3 25 | $3.7B | $3.6B | ||
| Q2 25 | $3.7B | $3.5B | ||
| Q1 25 | $3.6B | $3.3B | ||
| Q4 24 | $3.5B | $3.3B | ||
| Q3 24 | $3.6B | $3.3B | ||
| Q2 24 | $3.7B | $3.2B | ||
| Q1 24 | $3.8B | $3.2B |
净利润ADNTLH
| Q4 25 | $-22.0M | $164.7M | ||
| Q3 25 | $18.0M | $261.1M | ||
| Q2 25 | $36.0M | $237.9M | ||
| Q1 25 | $-335.0M | $212.8M | ||
| Q4 24 | $0 | $143.4M | ||
| Q3 24 | $79.0M | $169.3M | ||
| Q2 24 | $-11.0M | $205.3M | ||
| Q1 24 | $-70.0M | $228.0M |
毛利率ADNTLH
| Q4 25 | 6.0% | 28.2% | ||
| Q3 25 | 6.7% | 28.8% | ||
| Q2 25 | 6.3% | 29.7% | ||
| Q1 25 | 7.2% | 28.3% | ||
| Q4 24 | 6.2% | 26.9% | ||
| Q3 24 | 6.9% | 27.6% | ||
| Q2 24 | 5.6% | 28.8% | ||
| Q1 24 | 6.1% | 28.2% |
营业利润率ADNTLH
| Q4 25 | 1.1% | 7.6% | ||
| Q3 25 | 1.7% | 11.1% | ||
| Q2 25 | 1.8% | 11.2% | ||
| Q1 25 | -7.3% | 9.7% | ||
| Q4 24 | 1.3% | 6.5% | ||
| Q3 24 | 1.8% | 7.7% | ||
| Q2 24 | 1.2% | 9.2% | ||
| Q1 24 | -1.1% | 10.1% |
净利率ADNTLH
| Q4 25 | -0.6% | 4.7% | ||
| Q3 25 | 0.5% | 7.3% | ||
| Q2 25 | 1.0% | 6.7% | ||
| Q1 25 | -9.3% | 6.4% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 2.2% | 5.2% | ||
| Q2 24 | -0.3% | 6.4% | ||
| Q1 24 | -1.9% | 7.2% |
每股收益（稀释后）ADNTLH
| Q4 25 | $-0.28 | $1.98 | ||
| Q3 25 | $0.17 | $3.12 | ||
| Q2 25 | $0.43 | $2.84 | ||
| Q1 25 | $-3.99 | $2.52 | ||
| Q4 24 | $0.00 | $1.72 | ||
| Q3 24 | $0.88 | $2.00 | ||
| Q2 24 | $-0.12 | $2.43 | ||
| Q1 24 | $-0.77 | $2.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $532.3M |
| 总债务越低越好 | $2.4B | — |
| 股东权益账面价值 | $1.7B | $8.6B |
| 总资产 | $8.8B | $18.4B |
| 负债/权益比越低杠杆越低 | 1.37× | — |
8季度趋势，按日历期对齐
现金及短期投资ADNTLH
| Q4 25 | — | $532.3M | ||
| Q3 25 | — | $598.1M | ||
| Q2 25 | — | $647.3M | ||
| Q1 25 | — | $369.4M | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $265.1M | ||
| Q1 24 | — | $99.3M |
总债务ADNTLH
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益ADNTLH
| Q4 25 | $1.7B | $8.6B | ||
| Q3 25 | $1.8B | $8.7B | ||
| Q2 25 | $1.8B | $8.5B | ||
| Q1 25 | $1.7B | $8.3B | ||
| Q4 24 | $1.9B | $8.1B | ||
| Q3 24 | $2.1B | $8.2B | ||
| Q2 24 | $1.9B | $8.0B | ||
| Q1 24 | $2.1B | $8.0B |
总资产ADNTLH
| Q4 25 | $8.8B | $18.4B | ||
| Q3 25 | $9.0B | $18.3B | ||
| Q2 25 | $8.8B | $18.1B | ||
| Q1 25 | $8.6B | $17.6B | ||
| Q4 24 | $8.5B | $18.4B | ||
| Q3 24 | $9.4B | $18.6B | ||
| Q2 24 | $9.1B | $16.7B | ||
| Q1 24 | $9.3B | $16.5B |
负债/权益比ADNTLH
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.28× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 1.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $80.0M | $614.2M |
| 自由现金流经营现金流 - 资本支出 | $15.0M | $490.3M |
| 自由现金流率自由现金流/营收 | 0.4% | 13.9% |
| 资本支出强度资本支出/营收 | 1.8% | 3.5% |
| 现金转化率经营现金流/净利润 | — | 3.73× |
| 过去12个月自由现金流最近4个季度 | $174.0M | $1.2B |
8季度趋势，按日历期对齐
经营现金流ADNTLH
| Q4 25 | $80.0M | $614.2M | ||
| Q3 25 | $213.0M | $387.2M | ||
| Q2 25 | $172.0M | $620.6M | ||
| Q1 25 | $-45.0M | $18.5M | ||
| Q4 24 | $109.0M | $777.2M | ||
| Q3 24 | $263.0M | $277.3M | ||
| Q2 24 | $158.0M | $561.1M | ||
| Q1 24 | $81.0M | $-29.8M |
自由现金流ADNTLH
| Q4 25 | $15.0M | $490.3M | ||
| Q3 25 | $134.0M | $280.5M | ||
| Q2 25 | $115.0M | $542.7M | ||
| Q1 25 | $-90.0M | $-107.5M | ||
| Q4 24 | $45.0M | $665.1M | ||
| Q3 24 | $191.0M | $161.5M | ||
| Q2 24 | $88.0M | $432.9M | ||
| Q1 24 | $12.0M | $-163.6M |
自由现金流率ADNTLH
| Q4 25 | 0.4% | 13.9% | ||
| Q3 25 | 3.6% | 7.9% | ||
| Q2 25 | 3.1% | 15.4% | ||
| Q1 25 | -2.5% | -3.2% | ||
| Q4 24 | 1.3% | 20.0% | ||
| Q3 24 | 5.4% | 4.9% | ||
| Q2 24 | 2.4% | 13.4% | ||
| Q1 24 | 0.3% | -5.2% |
资本支出强度ADNTLH
| Q4 25 | 1.8% | 3.5% | ||
| Q3 25 | 2.1% | 3.0% | ||
| Q2 25 | 1.5% | 2.2% | ||
| Q1 25 | 1.2% | 3.8% | ||
| Q4 24 | 1.8% | 3.4% | ||
| Q3 24 | 2.0% | 3.5% | ||
| Q2 24 | 1.9% | 4.0% | ||
| Q1 24 | 1.8% | 4.2% |
现金转化率ADNTLH
| Q4 25 | — | 3.73× | ||
| Q3 25 | 11.83× | 1.48× | ||
| Q2 25 | 4.78× | 2.61× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 5.42× | ||
| Q3 24 | 3.33× | 1.64× | ||
| Q2 24 | — | 2.73× | ||
| Q1 24 | — | -0.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADNT
暂无分部数据
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
